Literature DB >> 21272753

Genetic warfarin dosing: tables versus algorithms.

Brian S Finkelman1, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel.   

Abstract

OBJECTIVES: The aim of this study was to compare the accuracy of genetic tables and formal pharmacogenetic algorithms for warfarin dosing.
BACKGROUND: Pharmacogenetic algorithms based on regression equations can predict warfarin dose, but they require detailed mathematical calculations. A simpler alternative, recently added to the warfarin label by the U.S. Food and Drug Administration, is to use genotype-stratified tables to estimate warfarin dose. This table may potentially increase the use of pharmacogenetic warfarin dosing in clinical practice; however, its accuracy has not been quantified.
METHODS: A retrospective cohort study of 1,378 patients from 3 anticoagulation centers was conducted. Inclusion criteria were stable therapeutic warfarin dose and complete genetic and clinical data. Five dose prediction methods were compared: 2 methods using only clinical information (empiric 5 mg/day dosing and a formal clinical algorithm), 2 genetic tables (the new warfarin label table and a table based on mean dose stratified by genotype), and 1 formal pharmacogenetic algorithm, using both clinical and genetic information. For each method, the proportion of patients whose predicted doses were within 20% of their actual therapeutic doses was determined. Dosing methods were compared using McNemar's chi-square test.
RESULTS: Warfarin dose prediction was significantly more accurate (all p < 0.001) with the pharmacogenetic algorithm (52%) than with all other methods: empiric dosing (37%; odds ratio [OR]: 2.2), clinical algorithm (39%; OR: 2.2), warfarin label (43%; OR: 1.8), and genotype mean dose table (44%; OR: 1.9).
CONCLUSIONS: Although genetic tables predicted warfarin dose better than empiric dosing, formal pharmacogenetic algorithms were the most accurate. Copyright Â
© 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272753      PMCID: PMC3107000          DOI: 10.1016/j.jacc.2010.08.643

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

Review 1.  A review of enzyme induction of warfarin metabolism with recommendations for patient management.

Authors:  J S Cropp; H I Bussey
Journal:  Pharmacotherapy       Date:  1997 Sep-Oct       Impact factor: 4.705

2.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

Authors:  Deepak Voora; Charles Eby; Mark W Linder; Paul E Milligan; Bonny L Bukaveckas; Howard L McLeod; William Maloney; John Clohisy; R Steven Burnett; Leonard Grosso; Susan K Gatchel; Brian F Gage
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

3.  Interindividual variability in sensitivity to warfarin--Nature or nurture?

Authors:  R Loebstein; H Yonath; D Peleg; S Almog; M Rotenberg; A Lubetsky; J Roitelman; D Harats; H Halkin; D Ezra
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

4.  An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.

Authors:  John F Carlquist; Benjamin D Horne; Chrissa Mower; James Park; John Huntinghouse; Jason T McKinney; Joseph B Muhlestein; Jeffrey L Anderson
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

5.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

6.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

7.  CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Authors:  Y Caraco; S Blotnick; M Muszkat
Journal:  Clin Pharmacol Ther       Date:  2007-09-12       Impact factor: 6.875

8.  Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.

Authors:  H Schelleman; J Chen; Z Chen; J Christie; C W Newcomb; C M Brensinger; M Price; A S Whitehead; C Kealey; C F Thorn; F F Samaha; S E Kimmel
Journal:  Clin Pharmacol Ther       Date:  2008-07-02       Impact factor: 6.875

Review 9.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  44 in total

Review 1.  Emerging Role of Precision Medicine in Cardiovascular Disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Circ Res       Date:  2018-04-27       Impact factor: 17.367

Review 2.  Pharmacogenetics of warfarin: challenges and opportunities.

Authors:  Ming Ta Michael Lee; Teri E Klein
Journal:  J Hum Genet       Date:  2013-05-09       Impact factor: 3.172

Review 3.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

4.  Empiric evidence for a genetic contribution to predisposition to surgical site infection.

Authors:  James P Lee; Harriet W Hopf; Lisa A Cannon-Albright
Journal:  Wound Repair Regen       Date:  2013-02-25       Impact factor: 3.617

5.  Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.

Authors:  Caroline S Fox; Jennifer L Hall; Donna K Arnett; Euan A Ashley; Christian Delles; Mary B Engler; Mason W Freeman; Julie A Johnson; David E Lanfear; Stephen B Liggett; Aldons J Lusis; Joseph Loscalzo; Calum A MacRae; Kiran Musunuru; L Kristin Newby; Christopher J O'Donnell; Stephen S Rich; Andre Terzic
Journal:  Circulation       Date:  2015-04-16       Impact factor: 29.690

Review 6.  Applied pharmacogenomics in cardiovascular medicine.

Authors:  Peter Weeke; Dan M Roden
Journal:  Annu Rev Med       Date:  2013-10-02       Impact factor: 13.739

7.  Warfarin pharmacogenetics: a rising tide for its clinical value.

Authors:  Julie A Johnson
Journal:  Circulation       Date:  2012-03-19       Impact factor: 29.690

Review 8.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

Review 9.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

Review 10.  Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Authors:  Charles Eby
Journal:  Semin Thromb Hemost       Date:  2012-10-09       Impact factor: 4.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.